Eisai Withdraw Application for Additional Indication of Aricept® for Treatment of Severe Alzheimer's Disease in Europe

Eisai Limited (Headquaters: London, Managing Director: Paul Hooper), the U.K. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito), today announced that the company has tentatively withdrawn its application for an additional indication for Aricept® in the treatment of severe Alzheimer's disease, submitted through the mutual recognition procedure in Europe. Eisai will discuss the matter with the European regulatory authorities and review possibilities for resubmission.

The Aricept®'s indication in the treatment of severe Alzheimer's disease has already been approved in the USA, India, New Zealand and Philippines. In addition, the application has been submitted in Japan.

Eisai will continue to undertake activities to help patients who are suffering from Alzheimer's disease.


Corporate Communications Department
Eisai Co., Ltd.